Primordial Genetics today announced the first closing of its Series A-2 financing round, including a group of 5 private investors.
The company will use the capital it has raised to support additional R&D activities to develop superior microbial strains for production of high-value proteins including human therapeutic proteins and industrial enzymes.
Primordial Genetics closes new financing round and adds private equity investors
Related Posts
Primordial Genetics Receives $55K I-Corps™ at NIH Grant for Enzymatic DNA Synthesis Market Survey
Team PrimordialApril 29, 2021
Primordial Genetics Awarded $1.15M Grant from the National Institute of General Medical Sciences for Revolutionary Ways to Manufacture Therapeutics and Vaccines
Team PrimordialAugust 6, 2020
Primordial Genetics and Denovium Collaborate to Impact the Diagnosis, Prevention & Treatment of Human Diseases
Team PrimordialMay 6, 2020